Modimelanotide

N/A

Report date: 2022/11/25 17:31:44
NME

Base Information

Drug NameModimelanotide
Drug Alias Name莫美兰肽modimelanotidummodimelanotida莫迪美诺肽ZP-1480 +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionMelanocortin receptor 4 agonistsMelanocortin receptor 1 agonistsMelanocortin receptor 5 agonists +[4] 
TargetsMelanocortin receptor 3Melanocortin receptor 1Melanocortin receptor 5 +[4] 
Therapy Area/IndicationsAortic AneurysmHeart DiseasesAcute Kidney Injury +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmark
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesZealand Pharma A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAction PharmaAbbvie Inc
Active IndicationsN/A
Inactive IndicationsAortic AneurysmHeart DiseasesAcute Kidney Injury +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia